Are placebo controls necessary to test new antidepressants and anxiolytics?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
One measure of a treatment's effectiveness is the regularity with which it proves superior to placebo. That measure also tells us about the consequences of using a treatment as a standard against which to test a new agent. To assess the frequency with which approved and presumably effective antidepressants and anxiolytics show statistical superiority over placebo, we reviewed placebo-controlled clinical trials of antidepressants and anxiolytics in a singularly large database free of publication bias. We evaluated clinical-trial data from the nine antidepressants approved by the FDA between 1985 and 2000. These trials comprised 10030 depressed patients who participated in 52 antidepressant clinical trials evaluating 93 treatment arms of a new or established antidepressant. Similarly, we examined clinical trials data from the 13 anxiolytics approved by the FDA between 1985 and 2000. These trials comprised 8,340 anxious patients, 40 anxiolytic clinical trials and 75 treatment arms of a new or established anxiolytic. Fewer than half (48%, 45/93) of the antidepressant treatment arms showed superiority to placebo. Among anxiolytics, 48% (36/75) of anxiolytic treatment arms showed superiority over placebo. These data suggest that conventional psychopharmacologic treatments for depression and anxiety are superior to placebo less than half the time and call into serious question the widely propagated notion that placebo controls can be dispensed with in clinical trials of these agents. Exclusion of placebo controls in favour of non-inferiority trials would result in a high likelihood that ineffective antidepressants and anxiolytics would be foisted on the public and, less dangerous but also problematic, that potentially effective agents would be missed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“These data, in combination with other recent reports showing increasing magnitude of placebo response (Walsh et al., 2002) and two failed trials (Hypericum Depression Trial Study Group, 2002 ; Shelton et al., 2001) with St John’s Wort, bolster the idea of using placebo.”
Result
Cited by
Fried, E. I., & Nesse, R. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.010 · Cited by 1,043
Exercise and Pharmacotherapy in the Treatment of Major Depressive Disorder
Blumenthal, J. A., Babyak, M. A., Doraiswamy, P. M., Watkins, L., Hoffman, B. M., Barbour, K. A., Herman, S., Craighead, W. E., Brosse, A. L., Waugh, R., et al. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318148c19a · Cited by 1,019
“sponse (36,37), which often takes the form of a clinically significant response”
BackgroundDepression sum-scores don’t add up: why analyzing specific depression symptoms is essential
Fried, E. I., & Nesse, R. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0325-4 · Cited by 981
“Several large meta-analyses of clinical trials have demonstrated that antidepressants outperform placebos in less than half of the trials, and that clinically relevant improvements can be documented only for a minority of severely depressed patients [32-34].”
BackgroundThe neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Metadata
- Authors
- Khan, A., Khan, S., & Brown, W. A.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-09
- Volume
- 5
- Issue
- 03
- Pages
- 193-7
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2160836626
- Cited by
- 130
- References
- 1
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Are placebo controls necessary to test new antidepressants and anxiolytics? https://app.cochat.ai/papers/10.1017/s1461145702002912
- The paper
- Khan, A., Khan, S., & Brown, W. A. (2002). Are placebo controls necessary to test new antidepressants and anxiolytics? The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145702002912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.